Felice Gragnano

Assitant Professor

University of Campania “Luigi Vanvitelli”

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Felice Gragnano is an Assistant Professor at the University of Campania "Luigi Vanvitelli" in Italy. His research focuses on cardiovascular health, particularly in relation to antithrombotic therapy, anticoagulation strategies, and the implications of chronic inflammatory diseases on cardiovascular risk. His recent publications explore topics such as antiplatelet therapy post-percutaneous coronary intervention, the clinical utility of digitoxin, and the risks associated with long-term anticoagulation treatments.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Marco Castelli

University of Verona

ITALY

View details

Giuseppe Andò

Associate Professor of Cardiovascular Diseases

Università degli Studi di Palermo

ITALY

View details

Paolo Calabrò

University of Campania “Luigi Vanvitelli”

ITALY

View details

Plinio Cirillo

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Felice Gragnano

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Narrative Review

Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study

Chronic Inflammatory Diseases and Cardiovascular Risk: Current Insights and Future Strategies for Optimal Management

When More Is Worse: Aspirin Backfires in Anticoagulated Post-PCI Patients

An Old Drug in a New Era: Digitoxin in the Spotlight After DIGIT-HF

From Discordance to Precision

Long-term antiplatelet monotherapy after PCI: searching for the smart choice

P2Y 12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials

Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention

AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain

The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance

What is new in the 2023 AHA/ACC Multisociety guideline on Chronic coronary Disease?

Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

What's new in pharmacotherapy at ESC Congress 2023?

Bleeding in Patients Undergoing PCI and TAVR

Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry

SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection

De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events

The latest news from American College of Cardiology 2023

Collaborators (4)

Marco Castelli

Giuseppe Andò

Paolo Calabrò

Plinio Cirillo

Make your next move.